Cushing’s syndrome (CS) is a rare neuroendocrine disease caused by persistent, excessive cortisol secretion. Many patients suffer significant co-morbidities, and most experience delays in diagnosis and treatment. During active CS through at least the short-term post-surgical period, patients are at increased risk of infections and, frequently, poorly managed hypertension and glucose intolerance / insulin resistance. The COVID-19 pandemic thus presented this rare patient population with an unprecedented challenge to mitigate. We examined self-reported pandemic-related behaviors of CS patients who are members of the US-based patient advocacy organization Cushing’s Support & Research Foundation (CSRF). An online survey analyzing behaviors related to CS status, adverse effects of quarantine, and adaptive measures engaged as a result of the COVID-19 pandemic was designed and shared with members of CSRF. Of 274 total responses, 91.2% (n=250) of members indicated that they had not become infected with COVID-19 as of the time of survey completion, whereas 8.8% (n=24) had caught the virus. The majority of respondents (78.5%, n=215) are post-surgical and in remission; the remaining 21.5% (n=59) are experiencing recurrence, diagnosed but not yet treated, or still in the diagnostic phase. About two-thirds of respondents (66.4%, n=182) reported making changes to their routine immediately or within the first week of hearing about the pandemic. Most (89.8%, n=246) have habitually worn a mask throughout 2020 and into 2021, but in some cases it has taken adverse experiences to alter behaviors. Among the patients diagnosed with COVID, five reported not wearing a mask before getting the virus, but four of those began wearing a mask after getting infected with the virus. Some patients reported postponing labs (38.7%, n=106), postponing MRIs or other radiology appointments (21.2%, n=58), and testing for the virus (13.5%, n=37) based solely on concern for potential increased risk of infection / severity of infection due to their history with CS. About a third of respondents (34.7%, n=95) also have temporary or permanent adrenal insufficiency (AI) due to CS, and a notable 38.9% (n=37) of these patients reported shortages of their regular cortisol-replacement medication at their regular pharmacy. Changing dosage and/or cutting pills is another response to shortages reported by 13.7% (n=13) of those experiencing AI. Quarantine restrictions are at times extreme and difficult to manage. Rare disease patients such as those with CS already adapt their conditions daily to a world that often doesn’t readily support or understand those adaptations. The results of this survey confirm that the added stress and uncertainty of adjusting further to the restrictions of quarantine have added significant burden to these patients. Social isolation and postponement of needed tests and procedures in particular have contributed to a decreased quality of life for CS patients during the COVID-19 pandemic.